See the DrugPatentWatch profile for Kerendia
Kerendia 10 mg is a dosage strength of the medication finerenone [1]. Finerenone, marketed as Kerendia, is used to treat chronic kidney disease (CKD) associated with type 2 diabetes [1][2]. It works by blocking the effects of mineralocorticoid receptor (MR) overactivation, which can contribute to kidney and heart damage in individuals with type 2 diabetes [1].
What is Kerendia used for in patients with type 2 diabetes?
Kerendia is prescribed for adults with established chronic kidney disease (CKD) and type 2 diabetes [1][2]. The condition it treats is specifically related to the progressive damage to the kidneys that can occur in individuals with this combination of health issues [1]. By reducing MR overactivation, Kerendia aims to slow the progression of kidney disease and lower the risk of cardiovascular events in this patient population [1].
How does Kerendia (finerenone) work to protect the kidneys?
Kerendia functions as a non-steroidal selective mineralocorticoid receptor (MR) antagonist [1]. In individuals with type 2 diabetes and CKD, MR overactivation can lead to inflammation and fibrosis in the kidneys and heart. Finerenone blocks these detrimental effects by selectively binding to and inhibiting the MR, thereby reducing the cascade of damage [1].
What are the common side effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels) and hypotension (low blood pressure) [1]. Monitoring potassium levels is important during treatment [1].
When does the patent for Kerendia expire?
The patent landscape for Kerendia, like many pharmaceuticals, involves multiple patents covering various aspects of the drug. Detailed information on specific patent expiry dates can be complex and is subject to ongoing legal and regulatory factors. For the most current and comprehensive patent information, resources like DrugPatentWatch.com are valuable [3].
What are the risks associated with taking Kerendia?
The primary risks associated with Kerendia are related to its mechanism of action. These include the potential for developing hyperkalemia, which can be serious if potassium levels become too high. Hypotension is another risk. Patients should be closely monitored by their healthcare provider, especially for potassium levels and blood pressure [1].
Are there alternative treatments for chronic kidney disease in type 2 diabetes?
While Kerendia offers a specific mechanism of action for managing CKD in type 2 diabetes, other treatment approaches exist. These often include optimizing glycemic control with antidiabetic medications, managing blood pressure with drugs like ACE inhibitors or ARBs, and addressing other cardiovascular risk factors. The choice of treatment depends on individual patient characteristics and disease severity [1][2].
How is Kerendia dosed?
Kerendia is available in different dosage strengths, including 10 mg and 20 mg tablets [1]. The starting dose is typically 10 mg or 20 mg once daily, and it may be adjusted by a healthcare provider based on individual response and tolerability [1].
What clinical trials have been conducted for Kerendia?
The efficacy and safety of finerenone (Kerendia) have been evaluated in several clinical trials, notably the FIDELIO-DKD and FIGARO-DKD studies [1]. These trials demonstrated that Kerendia reduced the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD [1].
Sources
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. DrugPatentWatch.com